Latest News- Mono Vaccine Market: Meningococcal vaccine is expected to lead the Type segment during 2025-2029

The Mono Vaccine Market is being driven by Increase in pediatric population

The Mono Vaccine Market is expected to grow at a CAGR of 4.6% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 2665 million. The mono vaccine market is experiencing a surge in mergers and acquisitions (M&A) as organizations seek to expand their product portfolios and enhance market presence in rapidly developing economies like India, Brazil, China, and South Africa. To maintain competitive edges and market leadership, companies are pursuing inorganic growth strategies through M&A. For instance, in February 2024, AstraZeneca announced its acquisition of Icosavax, Inc., expanding its vaccine offerings and strengthening its market position. This trend is expected to continue, as companies seek to capitalize on the growing demand for vaccines in emerging markets. 

Get more information on Mono Vaccine Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Type
  • Meningococcal vaccine
  • Japanese encephalitis vaccine
  • Hepatitis vaccine
  • Yellow fever vaccine
  • Others
• Application
  • Adults
  • Children
• End-user
  • Hospitals
  • Specialty clinics
  • Research institutions
  • Pharmaceutical companies
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increase in pediatric population
• Initiatives from government agencies
• Recent drug approvals and product innovations

However, the market also witnesses some limitations, which are as follows:

• Challenges associated with the development, storage, and handling of vaccines
• Rising antimicrobial resistance
• Product recalls

Benefits of Buying Global Mono Vaccine Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Mono Vaccine Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Mono vaccine market encompasses various tuberculosis (TB) diagnostic tests, including the outdated "Old Tuberculin" method, which involves multiple punctures for an intradermal test to determine tuberculin sensitivity. TB screening programs utilize these tests for high-risk populations such as intravenous drug users, long-term care facilities, correctional institutions, mental institutions, and nursing homes/facilities. Diagnostic procedures include the Mantoux method, chest x-rays, and microbiological examinations, which may yield false negative results. Mono vaccines protect against specific pathogens like hepatitis B, Burkitt's lymphoma, Hodgkin's lymphoma, gastric carcinomas, and nasopharyngeal carcinoma. Rapid vaccination campaigns employ modern technologies like mRNA and viral vector platforms to target and confer immunity to various infectious diseases.

Market Research Overview

The Mono Vaccine Market is a segment of the larger global pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of various types of drugs, including generic, non-generic, and veterinary offerings. According to Technavio, the healthcare market size is determined by the collective revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors propelling the expansion of the pharmaceuticals market include the growing elderly population. By 2050, approximately one-quarter of the US population and by 2030 in Europe are forecasted to be over 60 years old, necessitating increased demand for healthcare solutions, including vaccines like Mono Vaccine.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/